Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obexelimab in IgG4-related disease
ISRCTN18188034Phase 3Active, not recruiting
- Sponsor
- Zenas BioPharma
- Start
- Sep 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of obexelimab in IgG4-related disease (IgG4-RD) (3 arms), sponsored by Zenas BioPharma. Started Sep 2022; status: active, not recruiting.
02
Drugs
obexelimab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on ISRCTN18188034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18188034.